March 3, 2026Open Access

Dual Specificity Phosphatase (DUSP22) promoter hypomethylation in cell-free DNA is associated with rheumatoid arthritis and its radiographic severity

Key Points

DUSP22 cfDNA methylation may serve as a promising biomarker for evaluating rheumatoid arthritis severity,
Findings indicate an association with clinical characteristics; larger studies are needed for validation.
Exploratory pilot study assessed cfDNA methylation regarding rheumatoid arthritis in diverse patients.
Moreover, DUSP22 hypomethylation could enhance non-invasive diagnostics in rheumatology.

Abstract

Our pilot study is the first to evaluate cfDNA methylation association to RA clinical characteristics. These exploratory findings suggest that DUSP22 cfDNA methylation may represent a promising non-invasive biomarker in rheumatoid arthritis, a hypothesis that warrants validation in larger and ethnically diverse populations.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Lissette Anthony Delgado-Cruzata

City University of New York

Milena Rodríguez Álvarez

State University of New York

Alorah D. Bliese

City University of New York

Journals

Frontiers in Medicine

Actions

Institutions

State University of New York

City University of New York

SUNY Downstate Health Sciences University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Dual Specificity Phosphatase (DUSP22) promoter hypomethylation in cell-free DNA is associated with rheumatoid arthritis and its radiographic severity

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider